Apogee Therapeutics appoints Mark C. McKenna as Chairman of Board

Apogee Therapeutics, Inc.

Mark C. McKenna appointed as Chairman and Class III director, effective August 17, 2023.
Former President, CEO, and Chairman of Prometheus Biosciences, acquired by Merck for ~$10.8B.
Previously President of Salix Pharmaceuticals and senior roles at Bausch + Lomb and Johnson & Johnson.
Annual compensation of $84,000 for Chair and committee roles; options for 50,000+100,000 shares vesting over 3 years.
McKenna holds B.S. from Arizona State and MBA from Azusa Pacific; brings I&I development and commercial expertise.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark C. McKenna

Chair of the Board

APGE · Apogee Therapeutics, Inc.

Effective: 2023-08-17
Filed: August 21, 2023, 7:59 PM ET

On August 17, 2023, the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) appointed Mark C. McKenna as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark C. McKenna was appointed as Chair of the Board at Apogee Therapeutics, Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

On August 17, 2023, the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) appointed Mark C. McKenna as a member of the Board.

View on SEC.gov

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-093684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.